Artivion Inc, formerly CryoLife Inc, is a medical device company. It specializes in the manufacturing, processing, and distribution of medical devices and implantable human tissues. The company's product portfolio includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion's products are primarily used in cardiac and vascular surgeries, catering to patients with aortic conditions. The company markets its products and preservation services directly to physicians in the US and Canada and utilizes independent distributors and subsidiaries in the EMEA, APAC, and LATAM regions. Artivion operates globally, with manufacturing centers in Kennesaw, Georgia; Austin, Texas and Hechingen, Germany. Artivion Inc is headquartered in Kennesaw, Georgia, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Artivion Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Artivion Inc Company Overview
- Artivion Inc Company Snapshot
- Artivion Inc Pipeline Products and Ongoing Clinical Trials Overview
- Artivion Inc - Pipeline Analysis Overview
- Business Description
- Artivion Inc - Key Facts
- Artivion Inc - Major Products and Services
- Artivion Inc Pipeline Products by Development Stage
- Artivion Inc Ongoing Clinical Trials by Trial Status
- Artivion Inc Pipeline Products Overview
- Antyllus
- Antyllus Product Overview
- Aortiger
- Aortiger Product Overview
- Artivion
- Artivion Product Overview
- Biodisc Nucleus Pulposus Replacement
- Biodisc Nucleus Pulposus Replacement Product Overview
- Bioglue Surgical Adhesive
- Bioglue Surgical Adhesive Product Overview
- CryoValve SGAV
- CryoValve SGAV Product Overview
- E-liac Stent Graft System
- E-liac Stent Graft System Product Overview
- E-liac Stent Graft System Clinical Trial
- E-Ventus SX
- E-Ventus SX Product Overview
- E-Vita Open Neo
- E-Vita Open Neo Product Overview
- E-Vita Open Neo Clinical Trial
- Neo 2.0
- Neo 2.0 Product Overview
- On-X Mechanical Aortic Valve - ELIQUIS
- On-X Mechanical Aortic Valve - ELIQUIS Product Overview
- On-X Mitral Valve-Low INR
- On-X Mitral Valve-Low INR Product Overview
- Sanevo
- Sanevo Product Overview
- Semtis
- Semtis Product Overview
- Synergraft Xenograft Heart Valve
- Synergraft Xenograft Heart Valve Product Overview
- Synergraft Xenograft Vascular Graft
- Synergraft Xenograft Vascular Graft Product Overview
- Artivion Inc - Key Competitors
- Artivion Inc - Key Employees
- Artivion Inc - Key Employee Biographies
- Artivion Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Artivion Inc, Recent Developments
- Apr 29, 2024: Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
- Jan 29, 2024: Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting
- Nov 09, 2023: Artivion Announces Completion of Enrollment in PERSEVERE Trial
- Oct 19, 2023: Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results
- Oct 05, 2023: Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting
- May 30, 2023: ‘Korea Needs to Localize Rare Medical Devices Amid Global Supply Shortage’
- May 24, 2023: Artivion secures FDA PMA approval for PerClot
- Sep 26, 2022: Artivion halts clinical trial with mechanical aortic valve
- Aug 24, 2022: Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
- Jul 27, 2022: Artivion initiates enrollment in PERSEVERE Clinical Trial
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Artivion Inc Pipeline Products and Ongoing Clinical Trials Overview
- Artivion Inc Pipeline Products by Equipment Type
- Artivion Inc Pipeline Products by Indication
- Artivion Inc Ongoing Clinical Trials by Trial Status
- Artivion Inc, Key Facts
- Artivion Inc, Major Products and Services
- Artivion Inc Number of Pipeline Products by Development Stage
- Artivion Inc Pipeline Products Summary by Development Stage
- Artivion Inc Ongoing Clinical Trials by Trial Status
- Artivion Inc Ongoing Clinical Trials Summary
- Antyllus - Product Status
- Antyllus - Product Description
- Aortiger - Product Status
- Aortiger - Product Description
- Artivion - Product Status
- Artivion - Product Description
- Biodisc Nucleus Pulposus Replacement - Product Status
- Biodisc Nucleus Pulposus Replacement - Product Description
- Bioglue Surgical Adhesive - Product Status
- Bioglue Surgical Adhesive - Product Description
- CryoValve SGAV - Product Status
- CryoValve SGAV - Product Description
- E-liac Stent Graft System - Product Status
- E-liac Stent Graft System - Product Description
- E-liac Stent Graft System - Prospective Multicenter Registry to Examine the Real-world Performance of the E-liac Stent Graft System for Treatment of Uni- or Bilateral Aorto-iliac or Iliac Aneurysms
- E-Ventus SX - Product Status
- E-Ventus SX - Product Description
- E-Vita Open Neo - Product Status
- E-Vita Open Neo - Product Description
- E-Vita Open Neo - A Post-market Clinical Follow-up Study in Patients with Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated with E-vita OPEN NEO: NEOS
- E-Vita Open Neo - NEO - E-vita Open Neo Treatment of Aortic Arch Aneurysms and Dissections
- E-Vita Open Neo - NEOS-APAC - Asian Pacific Post-market Clinical Follow-up Study in Patients with Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated with E-vita OPEN NEO
- Neo 2.0 - Product Status
- Neo 2.0 - Product Description
- On-X Mechanical Aortic Valve - ELIQUIS - Product Status
- On-X Mechanical Aortic Valve - ELIQUIS - Product Description
- On-X Mitral Valve-Low INR - Product Status
- On-X Mitral Valve-Low INR - Product Description
- Sanevo - Product Status
- Sanevo - Product Description
- Semtis - Product Status
- Semtis - Product Description
- Synergraft Xenograft Heart Valve - Product Status
- Synergraft Xenograft Heart Valve - Product Description
- Synergraft Xenograft Vascular Graft - Product Status
- Synergraft Xenograft Vascular Graft - Product Description
- Artivion Inc, Key Employees
- Artivion Inc, Key Employee Biographies
- Artivion Inc, Subsidiaries
- Glossary
- Artivion Inc Pipeline Products by Equipment Type
- Artivion Inc Pipeline Products by Development Stage
- Artivion Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Orthofix Medical Inc
- Ethicon US LLC
- Edwards Lifesciences Corp
- Cutera Inc
- Advanced Medical Solutions Group Plc
- MAQUET, Inc.
- Pfizer Inc
- Medtronic Plc
- CR Bard Inc
- Nevro Corp
- iRhythm Technologies Inc
- AngioDynamics Inc
